1887 completed, 394 unknown, 381 terminated, 300 recruiting. 3370 Phase 1, 1163 Phase 2.
Follow Vascular Diseases: new trials by email Literature Review of Vascular Diseases trials Research Report on Vascular Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| FGF-1 for Intramuscular Injection for the Treatment of Peripheral Arterial Disease FGF-1, Placebo - Peripheral Arterial Disease, Stenosis | Phase 1 / Phase 2 | Not yet recruiting | Venturis Therapeutics, Inc. | 24 | 2028-10-15 | 2026-08-19 |
| Engineered Dendritic Cell Vaccines for Multiple Myeloma DC vaccines - Multiple Myeloma or Plasmacytoma | Phase 1 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 10 | 2027-06-30 | 2026-08-27 |
| ²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma Allogeneic Hematopoietic Stem Cell Transplantation, Astatine At 211 Anti-CD38 Monoclonal Antibody OKT10-B10, Cyclophosphamide - Multiple Myeloma, Recurrent Multiple Myeloma | Phase 1 | Withdrawn | Fred Hutchinson Cancer Center | 2027-06-01 | 2026-09-11 | |
| Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 162 | 2027-04-12 | 2026-10-16 |
| Placental Cells for Diabetic Foot Ulcers Placenta Stem Cells - Diabetic Foot Ulcer | Phase 1 | Not yet recruiting | Wake Forest University Health Sciences | 12 | 2027-03-01 | 2026-10-23 |
| A Basket Clinical Study to Assess Glycerol Tributyrate in Patients With Mitochondrial Encephalopathy, Lactic Acidosis, Stroke-like Episodes (MELAS) or Leber's Hereditary Optic Neuropathy-Plus (LHON-Plus) Glycerol Tributyrate - MELAS Syndrome, Lebers Hereditory Optic Neuropathy With Extra Ocular Symptoms (LHON-Plus) | Phase 1 / Phase 2 | Not yet recruiting | George Washington University | 24 | 2027-03-01 | 2026-10-05 |
| Microbiome Intervention for CAR-T Optimization and Response (MICRO-CART) Live Biotherapeutic Product (LBP), Placebo - Lymphoma, B-Cell, Multiple Myeloma | Phase 1 | Not yet recruiting | University of Chicago | 32 | 2027-02-23 | 2026-10-22 |
| Regenerative Medicine for Joint Hypermobility and Instability Dextrose 20% Prolotherapy, Autologous Platelet-Rich Plasma, Doxycycline Hyclate Injectable (Investigational) - Ehlers-Danlos Syndrome Hypermobility Type (hEDS), Ehlers-Danlos Syndrome (EDS) | Phase 1 / Phase 2 | Not yet recruiting | Manhattan Pain Medicine, PLLC | 100 | 2027-01-15 | 2026-10-06 |
| Ventricular mTOR Inhibition to Prevent Hydrocephalus After Brain Hemorrhage Sirolimus (Rapamune®) - Post-hemorrhagic Hydrocephalus (PHH) | Phase 1 / Phase 2 | Not yet recruiting | Massachusetts General Hospital | 15 | 2027-01-01 | 2026-06-25 |
| Relaxin Therapy for Atrial Fibrillation Relaxin, Placebo - Atrial Fibrillation (AF), Arrhythmia | Phase 1 / Phase 2 | Not yet recruiting | Deeptankar DeMazumder | 208 | 2027-01-01 | 2026-01-22 |
| Intra-Arterial Bevacizumab as an Adjunct to Middle Meningeal Artery Embolization for Chronic Subdural Hematoma Bevacizumab (intra-arterial) - Chronic Subdural Hematoma | Phase 1 | Not yet recruiting | Dheeraj Gandhi | 18 | 2027-01-01 | 2026-07-27 |
| The Safety and Efficacy of Human Umbilical Cord Mesenchymal Stem Cells (19#iSCLife®-ACI) in the Treatment of Acute Cerebral Infarction Allogeneic umbilical cord mesenchymal stem cells (SCLnow 19#), Aspirin Tablet - Cerebral Infarction | Phase 1 | Suspended | Sclnow Biotechnology Co., Ltd. | 40 | 2026-12-31 | 2026-04-23 |
| Phase 1b Study of TX002100 in Participants With Hematologic Support-Dependent Hereditary Hemorrhagic Telangiectasia (HHT) TX002100 - Hereditary Hemorrhagic Telangiectasia (HHT) | Phase 1 | Not yet recruiting | Tectonic Operating Company, Inc. | 20 | 2026-12-31 | 2026-10-15 |
| Human Umbilical Cord Mesenchymal Stem Cell Therapy (19#iSCLife®-CI) for Cerebral Infarction Patients in Convalescent Period. Allogeneic umbilical cord mesenchymal stem cell, Aspirin Enteric-coated Tablets & Atorvastatin Calcium - Cerebral Infarction | Phase 1 / Phase 2 | Suspended | Sclnow Biotechnology Co., Ltd. | 40 | 2026-12-31 | 2026-04-23 |
| Frontline Combination CAR-T Cell Therapy for Multiple Myeloma or Plasmacytoma CAR-T cells - Multiple Myeloma, Plasmacytoma | Phase 1 / Phase 2 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 20 | 2026-12-31 | 2026-08-27 |
| Multi-CAR T Cell Therapy in the Treatment of Multiple Myeloma CAR T cells - Multiple Myeloma | Phase 1 / Phase 2 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 20 | 2026-12-31 | 2026-10-30 |
| Bridge to Lung Transplant With Trans-septal Extra-corporeal Membrane Oxygenation (ECMO) for Right Heart Failure From Pulmonary Hypertension Protek Solo Transseptal Cannula - Lung Transplant, Pulmonary Hypertension | Phase 1 | Recruiting | Mayo Clinic | 4 | 2026-12-11 | 2026-07-31 |
| Evaluation of Superiority of Valsartan+Celecoxib+Metformin Over Metformin Alone in Type 2 Diabetes Patients Metformin, Val, Cel and Met XR Low, Val, Cel and Met XR High - Type 2 Diabetes, High Blood Pressure | Phase 1 / Phase 2 | Withdrawn | ARKAY Therapeutics | 2026-12-10 | 2026-07-16 | |
| Etenta-Isa-VRd in Newly Diagnosed High-Risk Multiple Myeloma Etentamig, Isatuximab, Bortezomib + Lenalidomide + Dexamethasone - Myeloma Multiple, Myeloma | Phase 1 / Phase 2 | Not yet recruiting | Universitätsklinikum Hamburg-Eppendorf | 220 | 2026-12-01 | 2026-05-20 |
| Study of Belantamab Mafodotin, Cevostamab, Pomalidomide for RRMM Patients (MAPLE) Belamaf, Cevostamab, Pomalidomide - Relapsed Refractory Multiple Myeloma (RRMM) | Phase 1 | Not yet recruiting | Canadian Myeloma Research Group | 108 | 2026-12-01 | 2026-09-21 |
Showing 20 of 3370. Sign in to see all of them.
Multiple Myeloma (1190) · Hypertension (359) · Stroke (282) · Lymphoma, Non-Hodgkin (243) · Leukemia, Lymphocytic, Chronic, B-Cell (237) · Lymphoma, Follicular (213) · Lymphoma, Mantle-Cell (211) · Waldenstrom Macroglobulinemia (211) · Lymphoma, B-Cell, Marginal Zone (199) · Lymphoma, Large B-Cell, Diffuse (194) · Recurrence (187) · Lymphoma (184) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (173) · Neoplasms, Plasma Cell (168) · Hodgkin Disease (164)
Cardiovascular Diseases (3298) · Immune System Diseases (1452) · Hemic and Lymphatic Diseases (1427) · Hematologic Diseases (1384) · Hemorrhagic Disorders (1378) · Hemostatic Disorders (1356) · Neoplasms by Histologic Type (1351) · Immunoproliferative Disorders (1334) · Blood Protein Disorders (1332) · Lymphoproliferative Disorders (1328) · Paraproteinemias (1325) · Neoplasms (1294) · Neoplasms, Plasma Cell (1174) · Pathological Conditions, Signs and Symptoms (1007)
Dexamethasone (267) · Lenalidomide (140) · Bortezomib (133) · Cyclophosphamide (125) · Calcium Dobesilate (99) · pomalidomide (83) · carfilzomib (72) · Melphalan (68) · fludarabine (66) · daratumumab (61) · fludarabine phosphate (53) · Rituximab (50) · Filgrastim (41) · Sodium Chloride (38) · Peripheral Blood Stem Cell Transplantation (35)
National Cancer Institute (NCI) (72) · GlaxoSmithKline (63) · Mayo Clinic (56) · Chong Kun Dang Pharmaceutical (54) · Boryung Pharmaceutical Co., Ltd (45) · Merck Sharp & Dohme LLC (36) · Celgene (34) · Bristol-Myers Squibb (32) · Bayer (26) · M.D. Anderson Cancer Center (26) · Memorial Sloan Kettering Cancer Center (26) · Novartis Pharmaceuticals (26) · Amgen (25) · AstraZeneca (24) · AbbVie (22)
United States (1806) · China (340) · South Korea (211) · Canada (172) · Germany (167) · Australia (157) · United Kingdom (155) · Spain (154) · France (153) · Italy (98) · Japan (89) · Netherlands (82) · Israel (79) · Taiwan (54) · Belgium (49)
Italo Biaggioni, MD (10)
PMID 34398557, PMID 33175411, PMID 36100310, PMID 37022569, PMID 24524452, PMID 28803351, PMID 32499241, PMID 34515338, PMID 35802393, PMID 37192741, PMID 11927799, PMID 12119802, PMID 15738343, PMID 18536865, PMID 19238148, PMID 19717023, PMID 22163120, PMID 22440499, PMID 24475026, PMID 24916507, PMID 26370838, PMID 26589907, PMID 26752061, PMID 26943915, PMID 27412889, PMID 27561272, PMID 30739747, PMID 31215818, PMID 31527168, PMID 33011075, PMID 33027067, PMID 33653620, PMID 33980831, PMID 34174279, PMID 36375120, PMID 36645250, PMID 36912792, PMID 37270762, PMID 37658205, PMID 39545461, PMID 40000533, PMID 40302153, PMID 40826257, PMID 41100731, PMID 41118600, PMID 42287565, PMID 42573020, PMID 10231466, PMID 10392863, PMID 10492412
2023 (41), 2018 (20), 2019 (20), 2015 (19), P30CA015083 (17), 2016 (12), 2009 (11), 2017 (11), U01CA076576 (9), 2014 (8), P30CA006973 (8), P30CA016058 (8), 2008 (7), 2025 (7), P30CA015704 (7)